Scientists create potent ‘degrader’ of cancer-driving protein 26 Apr 2023 Scientists at The Institute of Cancer Research, London, have created a compound that destroys a protein involved in driving cancers, including B-cell lymphoma. Find out more Show/Hide
‘Molecular glue degrader’ reaches cancer trial following ICR research programme 23 Feb 2023 The biotechnology company Monte Rosa Therapeutics – originally a spin-out from research at The Institute of Cancer Research, London – has announced that the first patient has received their ‘molecular glue degrader’ drug as part of a clinical trial in oncology. Find out more Show/Hide